

Ref. No: FOI1201
Date: 12/09/2024
Subject: Intra-vitreous injections or implants

REQUEST

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2024:

- **Aflibercept**
- **Bevacizumab - Avastin**
- **Bevacizumab - Biosimilar**
- **Brolucizumab**
- **Dexamethasone**
- **Faricimab**
- **Fluocinolone acetonide**
- **Ranibizumab - Lucentis (pre-filled syringes)**
- **Ranibizumab - Lucentis (vials)**
- **Ranibizumab - Ongavia**
- **Ranibizumab – Ximluci**

2. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2024

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

St. Helens and Knowsley response

Number of Injections/Implants: May to August 2024:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	724	130	169
Bevacizumab	4	0	0
Dexamethasone	0	4	3
Faricimab	307	94	2
Ranibizumab - Lucentis	0	0	0
Ranibizumab - Ongavia	252	44	5
Ranibizumab - Ximluci			

Southport and Ormskirk response

S&O do not undertake IV injections.